Premium
LncRNA PCAT‐1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin
Author(s) -
Zhen Qiang,
Gao Lina,
Wang Renfeng,
Chu Weiwei,
Zhang Yaxiao,
Zhao Xiaojian,
Lv Baolei,
Liu Jiabao
Publication year - 2018
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3314
Subject(s) - cisplatin , gene silencing , cancer research , in vivo , long non coding rna , cancer , growth inhibition , cell growth , medicine , biology , chemotherapy , gene , downregulation and upregulation , biochemistry , genetics , microbiology and biotechnology
Oesophageal cancer (OC) is one of the most fatal malignancies in the world, and chemoresistance restricts the therapeutic outcome of OC. Long noncoding RNA (lncRNA) was reported to play roles in multiple cancer types. Yet, the function of lncRNA in chemoresistance of OC has not been reported. A lncRNA gene, PCAT‐1, showed higher expression in OC tissues, especially higher in secondary OC compared with normal mucosa tissues. Overexpression of PCAT‐1 increased the proliferation rate and growth of OC cells. Inhibition of PCAT‐1 decreased proliferation and growth of OC cells, and increased cisplatin chemosensitivity. In a mouse OC xenograft model, PCAT‐1 inhibition repressed OC growth in vivo. Therefore, PCAT‐1 may potentially serve as a therapeutic target for treating OC. PCAT‐1 promotes development of OC and represses the chemoresistance of OC to cisplatin, and silencing of PCAT‐1 may be a therapeutic strategy for treating OC.